Selling cell thawing: Medcision launches early adopter scheme to push tech

By Gareth Macdonald

- Last updated on GMT

iStock/bestdesigns
iStock/bestdesigns

Related tags Clinical trial Technology

Medcision has started pushing its cell therapy thawing technology through an early adopter scheme designed to encourage adoption by firms with candidates in trials.

The idea is to make Thawstar – Medcision’s thawing technology that is designed to precisely control the preparation of frozen cell therapies – available to 30 companies and institutions during of early stage clinical trials.

According to Medcision, eliminating variability in thawing times, thereby improving the quality and comparability of clinical data.

Samuel Kent, chief commercial officer, told us "we are putting Thawstar cell thawing system into the hands of companies and investigators looking to de-risk thawing of cell therapies in clinical trials. By making this technology readily available, for free, we are contributing to the advancement of clinical trial successes which can be negatively impacted by variations in sample handling."

Kent added that: "We are confident that once users see first-hand the consistency and reproducible outcomes experienced with Thawstar they will evaluate all their non-standardized processes and will consider using MedCision’s thawing products going forward​." 

Thawing tech market heats up

Thawing is a hot topic for cell therapy developers. Most biopharmaceutical products are sensitive to temperature changes, but personalized cell therapies are particularly susceptible.

As a result cell therapies are usually frozen at the manufacturing facility before being shipped to the clinic for administration back to the patient.

Demand for thawing technologies has increased prompting the emergence of firm’s like Medcision, which was set up by laboratory tools developer Biocision last September.

Rivals like Asymptote​ have also recognized the surge in demand. In November​ the UK-firm launched CellSeal, a cell thawing system developed in collaboration with Cook Regenetec, a bioprocessing services firm spun-out of medical device maker Cook Medical.

Other firms like Sartorius​ are developing technologies to avoid potential problems during freezing and thawing operations.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us

Products

View more

Webinars